NEW YORK, Feb. 27, 2018 -- Global Chronic Idiopathic Constipation (CIC) Drugs Market is estimated to reach $2.96 billion by 2024 Says, Profshare Market Research; growing at a CAGR of 6.6% between 2016 and 2024.If the constipation happens chronically with an unidentifiable cause it is known as Chronic Idiopathic Constipation (CIC). The word “Idiopathic” means the cause is not known. Increasing awareness and widespread presence of idiopathic constipation are the key factors for growth of CIC drugs market. Currently CIC drugs market has huge opportunity for research and development.
Depending on type of drugs, global CIC drugs market is segmented into Lubiprostone, Linaclotide and others. Currently Lubiprostone drug segment dominates the market. But, due to its lower efficacy in comparison with others, patent loss and growing competition from Linaclotide, Lubiprostone will lose its dominance in the upcoming future. Depending on prescription types it is subdivided into prescribed drugs and over the counter drugs. After analysing the symptoms also, constipation is not considered as a disease but a condition, side effect or syndrome. Usually patients avoid to visit doctors to address the issue. Therefore approximately 65% of the CIC drugs market is covered by over the counter drugs. The top players of CIC drugs market are Actavis, Chugai Pharmaceutical, Ferring International Center S.A., Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding AG, Sanofi, Bayer AG, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc, Ironwood Pharmaceuticals and Progenics Pharmaceuticals.
Get Free Sample: https://www.profsharemarketresearch.com/sample/chronic-idiopathic-constipation-cic-drugs-market-sample/
Global Chronic Idiopathic Constipation (CIC) Drugs Market: End Users/Application Analysis
- Hospitals & Clinics
- Ambulatory Surgical Centres
- Long Term Care Centres
Global Chronic Idiopathic Constipation (CIC) Drugs Market: Product Type
- Lubiprostone
- Linaclotide
Report Enquiry: https://www.profsharemarketresearch.com/enquiry/chronic-idiopathic-constipation-cic-drugs-market-enquiry/
Global Chronic Idiopathic Constipation (CIC) Drugs Market: Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Chronic Idiopathic Constipation (CIC) Drugs:
- Actavis
- Chugai Pharmaceutical
- Ferring International Center S.A.
- Synergy Pharmaceuticals
- Pfizer
- GlaxoSmithKline
- Roche Holding AG
- Sanofi
- Bayer AG
- Salix Pharmaceuticals Ltd
- Sucampo Pharmaceuticals Inc
- Ironwood Pharmaceuticals
- Progenics Pharmaceuticals
Buy Report: https://www.profsharemarketresearch.com/buy/chronic-idiopathic-constipation-cic-drugs-market-buy-su/
Contact Us:
Mia Cox,
Email- [email protected]
Tel- 1-877-797-7295
www.profsharemarketresearch.com


SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
OpenAI Restricts Astra AI Over Cyberattack Risks
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 



